FASN and metabolic dysfunction-associated steatotic liver disease: It also suppresses pro-inflammatory and pro-fibrotic mediators, including transforming growth factor-beta (TGF-β), and reduces lipogenesis by downregulating lipogenic genes encoding fatty acid synthase (FASN) and acetyl-CoA carboxylase 1 (ACC1), both often elevated in MASLD [32,36].